Medication used to treat diabetes could reduce the risk of developing Parkinson’s, according to a number of research studies, providing potential treatment options for slowing, stopping or reversing Parkinson’s.


Latest updates

The exenatide phase 3 study protocol

Researchers conducting the phase 3 'Exenatide PD3' clinical trial have published the protocol of the study, which outlines the details of the trial. Cure...

Further support for diabetes treatments for Parkinson’s

A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development...

Further data on the relationship between diabetes and Parkinson’s

New research has found that there is convincing evidence that Type 2 diabetes is associated with a greater risk of Parkinson's, but may in...

Type 2 diabetes medications impact risk of Parkinson’s

In a recent study, researchers have concluded that the elevated risk of Parkinson’s in patients with type 2 diabetes might be mitigated depending on...

The liraglutide trial for people with Parkinson’s

This clinical trial will test the efficacy and safety of the diabetes drug liraglutide (a GLP-1 agonist) in people with Parkinson’s. The trial is...